Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Category: #health  By Pankaj Singh  Date: 2019-10-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis treatments.

Exicure Inc. is one such gene-regulating and immunomodulatory drug developer who has recently announced positive clinical results from its drug candidate XCUR17 in psoriasis at the 15th Annual Meeting of the OTS (Oligonucleotide Therapeutics Society) held in Munich.

Reportedly, Dr. David Giljohann, Chief Executive Officer, Exicure, presented the clinical data of XCUR17 at the session of Oligonucleotides Clinical Studies.

Sources close to the study claim that all enrolled patients received daily application of three strengths of XCUR17 vehicle gel and gel to different affected skin areas for twenty-five days. Biopsies were collected from the affected areas following 25-days of treatment as well as from lesional and nonlesional skin at baseline.

Clinical findings related with psoriasis-linked markers and histological variations from biopsies offered by patients showed that in the XCUR17 treatment:

  • There was a decrease in the levels of inflammation markers downstream and psoriasis of XCUR17's target, IL-17RA.
  • There was a substantial decrease in keratin 16 expression which is a key marker of psoriasis.
  • There was a reduction in the major inflammatory markers interleukin 36A, beta-defensin 4A and interleukin 19, versus psoriatic skin at baseline.
  • It showed clinical improvements that matched decreases in epidermal thickness and keratin 16 protein.

Prior to these attained outcomes, on 17 December 2018, Exicure had announced top-line results from Phase 1 trial assessing XCUR17 in patients who has mild-to-moderate chronic plaque psoriasis.

At that time, the highest strength XCUR17 gel indicated a statistically meaningful improvement in psoriasis affected skin. Such findings from the Phase 1 trial showed that SNA-based drugs like XCUR17 may use effectively in treating psoriasis.

Source Credit - https://www.businesswire.com/news/home/20191016005268/en/Exicure-Presents-Positive-Biomarker-Results-Clinical-Trial



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...